AVANIR Pharmaceuticals (FRA:AV2B) EBIT per Share : €-0.22 (TTM As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals EBIT per Share?

AVANIR Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2014 was €-0.06. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2014 was €-0.22.

During the past 3 years, the average EBIT per Share Growth Rate was -17.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -1.50% per year. During the past 10 years, the average EBIT per Share Growth Rate was -12.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for AVANIR Pharmaceuticals's EBIT per Share or its related term are showing as below:

FRA:AV2B' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 0 Med: -16.1 Max: 189.8
Current: -17.2

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of AVANIR Pharmaceuticals was 189.80% per year. The lowest was 0.00% per year. And the median was -16.10% per year.

FRA:AV2B's 3-Year EBIT Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.8 vs FRA:AV2B: -17.20

AVANIR Pharmaceuticals's EBIT for the three months ended in Sep. 2014 was €-10.45 Mil.

AVANIR Pharmaceuticals EBIT per Share Historical Data

The historical data trend for AVANIR Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals EBIT per Share Chart

AVANIR Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

EBIT per Share

Get a 7-Day Free Trial

-0.23

-0.37

-0.34

-0.38

-0.23

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
EBIT per Share	Get a 7-Day Free Trial															-0.17	-0.05	-0.06	-0.05	-0.06

AVANIR Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

AVANIR Pharmaceuticals's EBIT per Share for the fiscal year that ended in Sep. 2014 is calculated as

	EBIT per Share		(A: Sep. 2014 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-36.566	/	161.269
=	-0.23

AVANIR Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2014 is calculated as

	EBIT per Share		(Q: Sep. 2014 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.447	/	172.353
=	-0.06

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.22

AVANIR Pharmaceuticals (FRA:AV2B) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

AVANIR Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » EBIT per Share

Traded in Other Exchanges

N/A

Address

Website

http://www.avanir.com

Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines